Physician profile
Sunil A Mutgi
NPI 1225358906
$1,610.19
in general payments reported to CMS, 2019-2025
28 companies · $1,610 in 2025
The $1,610 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $1,610.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,578 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,577.92 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $278.82 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $194.14 | 2025 | Rexulti, Abilify Asimtufii |
| Tg Therapeutics, INC. | $161.94 | 2025 | |
| Alkermes, INC. | $143.46 | 2025 | Lybalvi, Aristada |
| Lilly USA, LLC | $120.52 | 2025 | Zepbound, Kisunla |
| Collegium Pharmaceutical, INC. | $73.78 | 2025 | Jornay Pm |
| Acadia Pharmaceuticals INC | $73.61 | 2025 | Nuplazid |
| Ipsen Biopharmaceuticals, INC | $50.86 | 2025 | Dysport |
| Tris Pharma INC | $48.00 | 2025 | Dyanavel Xr |
| Genentech USA, INC. | $37.72 | 2025 | Ocrevus Zunovo |
| Teva Pharmaceuticals USA, INC. | $34.25 | 2025 | Ajovy, Austedo Xr |
| Lundbeck LLC | $32.92 | 2025 | Vyepti |
| Novo Nordisk INC | $32.27 | 2025 | Wegovy |
| Janssen Biotech, INC. | $30.07 | 2025 | |
| Neurocrine Biosciences, INC. | $28.99 | 2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $28.79 | 2025 | Leqembi |
| Ucb, INC. | $28.51 | 2025 | Rystiggo |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $28.07 | 2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $24.53 | 2025 | Fanapt, Hetlioz |
| Scilex Pharmaceuticals INC. | $22.30 | 2025 | |
| Argenx US, INC. | $21.91 | 2025 | Vyvgart Hytrulo, Vyvgart |
| Supernus Pharmaceuticals, INC. | $18.10 | 2025 | Qelbree |
| Indivior INC. | $17.89 | 2025 | Sublocade |
| Axsome Therapeutics, INC. | $17.16 | 2025 | Sunosi |
| Amneal Pharmaceuticals LLC | $16.67 | 2025 | Crexont |
| Janssen Pharmaceuticals, INC | $15.82 | 2025 | Spravato |
| Pfizer INC. | $15.44 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.65 | 2025 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sunil Mutgi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.